$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

$ctor Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014850 Filed on April 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$244.1K	$1.013M
YoY Change		76.76%	633.47%
% of Gross Profit
Research & Development			$4.240M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses		$244.1K	$1.013M
YoY Change		76.76%	633.47%
Operating Profit	-$384.0K		-$1.013M
YoY Change	92.41%		633.5%
Interest Expense		$1.277M	$3.432M
YoY Change		146.18%	561.43%
% of Operating Profit
Other Income/Expense, Net	$636.4K		$3.432M
YoY Change	-21.99%		561.44%
Pretax Income		$1.033M	$2.419M
YoY Change		171.35%	535.3%
Income Tax			$576.0K
% Of Pretax Income			23.81%
Net Earnings	$252.5K	$1.033M	$2.419M
YoY Change	-59.04%	171.35%	535.3%
Net Earnings / Revenue
Basic Earnings Per Share	$0.04		$0.27
Diluted Earnings Per Share	$0.04	$0.12	$0.27
COMMON SHARES
Basic Shares Outstanding	6.653M shares	8.941M shares	6.600M shares
Diluted Shares Outstanding	4.312M shares		6.600M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$32.75K	$32.75K
YoY Change		-88.67%	-88.67%
Cash & Equivalents	$261.00	$32.75K
Short-Term Investments
Other Short-Term Assets		$25.45K	$25.45K
YoY Change		-71.14%	-71.14%
Inventory
Prepaid Expenses	$40.73K	$25.45K
Receivables
Other Receivables
Total Short-Term Assets	$40.99K	$58.20K	$58.20K
YoY Change	-91.13%	-84.58%	-84.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$72.57M	$72.57M
YoY Change		7.01%	7.01%
Other Assets
YoY Change
Total Long-Term Assets	$49.15M	$72.57M	$72.57M
YoY Change	-29.16%	7.01%	7.01%
TOTAL ASSETS
Total Short-Term Assets	$40.99K	$58.20K	$58.20K
Total Long-Term Assets	$49.15M	$72.57M	$72.57M
Total Assets	$49.19M	$72.62M	$72.62M
YoY Change	-29.57%	6.5%	6.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$485.8K	$375.9K	$380.9K
YoY Change	346.06%	1080.55%	1096.26%
Deferred Revenue
YoY Change
Short-Term Debt		$1.320M	$1.320M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.081M	$2.046M	$2.046M
YoY Change	564.17%	6325.94%	6325.13%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities		$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.081M	$2.046M	$2.046M
Total Long-Term Liabilities		$0.00	$0.00
Total Liabilities		$2.046M	$2.046M
YoY Change		6325.13%	6325.13%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.040M	-$1.988M
YoY Change	137461.86%	-675.71%
Common Stock	$167.00	$167.00
YoY Change	-30.99%	-30.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.040M	-$1.988M	$70.58M
YoY Change
Total Liabilities & Shareholders Equity	$49.19M	$72.62M	$72.62M
YoY Change	-29.57%	6.5%	6.5%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$252.5K	$1.033M	$2.419M
YoY Change	-59.04%	171.35%	535.3%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities		-$218.8K	-$601.3K
YoY Change		356.06%	1153.55%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$660.0K	-$1.320M
YoY Change		-99.02%	-98.04%
Cash From Investing Activities		-$660.0K	-$1.320M
YoY Change		-99.02%	-98.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		885.0K	$1.665M
YoY Change		-98.69%	-97.54%
NET CHANGE
Cash From Operating Activities		-218.8K	-$601.3K
Cash From Investing Activities		-660.0K	-$1.320M
Cash From Financing Activities		885.0K	$1.665M
Net Change In Cash		6.230K	-$256.4K
YoY Change		-97.85%	-188.68%
FREE CASH FLOW
Cash From Operating Activities		-$218.8K	-$601.3K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	TENK	Shareholder Receivable ShareholderReceivable		usd
CY2022Q4	TENK	Shareholder Receivable ShareholderReceivable		usd
CY2023	TENK	Changes In Derivative Liabilities ChangesInDerivativeLiabilities		usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2023	TENK	Payments For Underwriting Fees PaymentsForUnderwritingFees		usd
CY2023	TENK	Payments For Other Fees PaymentsForOtherFees		usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	TENK	Advance From Related Party Debt AdvanceFromRelatedPartyDebt		usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	420 Lexington Avenue
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2446
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10170
CY2023	dei	City Area Code CityAreaCode	(347)
CY2023	dei	Local Phone Number LocalPhoneNumber	627-0058
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	69498000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6653077	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Houston, TX
CY2023Q4	us-gaap	Cash Cash	32746	usd
CY2022Q4	us-gaap	Cash Cash	289175	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25454	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88169	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	58200	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	377344	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	72565394	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	67813020	usd
CY2023Q4	us-gaap	Assets Assets	72623594	usd
CY2022Q4	us-gaap	Assets Assets	68190364	usd
CY2023Q4	TENK	Accrued Offering Costs AccruedOfferingCosts	5001	usd
CY2022Q4	TENK	Accrued Offering Costs AccruedOfferingCosts	31836	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	375886	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2045762	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31836	usd
CY2023Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.99
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.27
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	72565394	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	67813020	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2341000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2341000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2416000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2416000	shares
CY2023Q4	TENK	Common Stock Shares Subject To Mandatory Redemption Number Of Shares CommonStockSharesSubjectToMandatoryRedemptionNumberOfShares	6600000	shares
CY2022Q4	TENK	Common Stock Shares Subject To Mandatory Redemption Number Of Shares CommonStockSharesSubjectToMandatoryRedemptionNumberOfShares	6600000	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	242	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	345266	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68190364	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	138115	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-138115	usd
CY2023	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	3432374	usd
CY2022	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	493020	usd
CY2022	TENK	Changes In Derivative Liabilities ChangesInDerivativeLiabilities	25906	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	518926	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	380811	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6600000	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6600000	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1341758	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1341758	shares
CY2023	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.27
CY2023	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.27
CY2022	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.12
CY2022	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.12
CY2023	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesSubjectToRedemption	2347986	shares
CY2023	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesSubjectToRedemption	2347986	shares
CY2022	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesSubjectToRedemption	1865478	shares
CY2022	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesSubjectToRedemption	1865478	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.27
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.12
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2023	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	4752374	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2419304	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1987562	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	25000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3940000	usd
CY2022	TENK	Stock Issued During Period Value Fair Value Of Public Rights StockIssuedDuringPeriodValueFairValueOfPublicRights	1056000	usd
CY2022	TENK	Stock Issued During Period Value Fair Value Of Underwriter Shares StockIssuedDuringPeriodValueFairValueOfUnderwriterShares	2922480	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	343845	usd
CY2022	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	7624825	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	380811	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	2419304	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	380811	usd
CY2023	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	3432374	usd
CY2022	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	493020	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-62715	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	88169	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	126422	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	349051	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	25988	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-601304	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47968	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	1320000	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	67320000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1320000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-67320000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	66000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3335987	usd
CY2022	TENK	Payments For Underwriting Fees PaymentsForUnderwritingFees	1320000	usd
CY2022	TENK	Payments For Other Fees PaymentsForOtherFees	253157	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	25000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	130687	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1320000	usd
CY2023	TENK	Advance From Related Party Debt AdvanceFromRelatedPartyDebt	344875	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1664875	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67657143	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-256429	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	289175	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	289175	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	289175	usd
CY2023	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	4752374	usd
CY2022	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	7624825	usd
CY2022Q4	TENK	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
CY2022Q4	TENK	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
CY2022Q4	TENK	Redemption Limit Percentage Without Prior Written Consent RedemptionLimitPercentageWithoutPriorWrittenConsent	0.15	pure
CY2022Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2022Q4	TENK	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	72565394	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	67813020	usd
CY2022Q4	us-gaap	Payments For Deposits PaymentsForDeposits	66667	usd
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.03
CY2022Q4	us-gaap	Share Price SharePrice	10.00
CY2023Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.03
CY2022	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	7624825	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zD6F6bsHDQCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_867_zR6RhaLuYGd1">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	67320000	usd
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.20
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	72565394	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	67813020	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount SharesSubjectToMandatoryRedemptionSettlementTermsAmount	66000000	usd
CY2022Q4	TENK	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	-1056000	usd
CY2022Q4	TENK	Offering Costs Allocated Ordinary Shares Subject To Redemption OfferingCostsAllocatedOrdinarySharesSubjectToRedemption	-4755805	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	67813020	usd
CY2023	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	4752374	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	72565394	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zLTodPS4nJS3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z8MQiXcZswJ5">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_90C_eus-gaap--CashFDICInsuredAmount_iI_c20231231_zWZM1R7oiQo8" title="FDIC insured amount">250,000</span>. The Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	120000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	21666	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	60000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	0	usd
CY2023Q4	us-gaap	Share Price SharePrice	10.00
CY2023Q3	us-gaap	Payments For Deposits PaymentsForDeposits	660000	usd
CY2023Q4	us-gaap	Payments For Deposits PaymentsForDeposits	660000	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2341000	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2341000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2416000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2416000	shares
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	225000	shares
CY2022Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	2922480	usd

Files In Submission

Name	View Source	Status
0001493152-24-014850-index-headers.html	Edgar Link	pending
0001493152-24-014850-index.html	Edgar Link	pending
0001493152-24-014850.txt	Edgar Link	pending
0001493152-24-014850-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tenk-20231231.xsd	Edgar Link	pending
tenk-20231231_def.xml	Edgar Link	unprocessable
tenk-20231231_lab.xml	Edgar Link	unprocessable
tenk-20231231_pre.xml	Edgar Link	unprocessable
tenk-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

2024 Q2 Form 10-K Financial Statement

#000149315224014850 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR CITIUS ONCOLOGY, INC. Stock $ctor

2024 Q2 Form 10-K Financial Statement

#000149315224014850 Filed on April 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor